ISSN: 2475-7640

臨床および実験的移植のジャーナル

オープンアクセス

当社グループは 3,000 以上の世界的なカンファレンスシリーズ 米国、ヨーロッパ、世界中で毎年イベントが開催されます。 1,000 のより科学的な学会からの支援を受けたアジア および 700 以上の オープン アクセスを発行ジャーナルには 50,000 人以上の著名人が掲載されており、科学者が編集委員として名高い

オープンアクセスジャーナルはより多くの読者と引用を獲得
700 ジャーナル 15,000,000 人の読者 各ジャーナルは 25,000 人以上の読者を獲得

抽象的な

Haploidentical Stem Cell Transplantation and Stem Cell Mobilization for Relapsed Neuroblastoma

Michael Holzer

Despite autologous stem cell transplantation, paediatric patients with refractory or relapsed metastatic neuroblastoma (NBL) have a poor prognosis (SCT). We tested this strategy in kids with very high risk NBL since allogeneic SCT from a haploidentical donor has an impressive alloreactive effect in leukaemia patients. Data from two prospective phase I/II trials were examined. A median of 17 106/kg T/B cell-depleted CD34+ stem cells with 68 103/kg residual T cells and 107 106/kg natural killer cells were given to 26 patients with refractory (n = 5), metastatic relapsed (n = 20), or locally relapsed (n = 1) MYCN-positive NBL. Melphalan, fludarabine, thiotepa, OKT3, and a brief course of mycophenolate mofetil were all included in the conditioning regimen. 96 percent of the patients experienced engraftment. overall survival and event-free Survival rates at 5 years were 19 and 23%, respectively. The lone fatality was brought about by progression or a subsequent relapse; no transplantation-related mortality was noted.